Select country change
Shopping cart (0 , 0,00 ) Menu Search
Distributed product

Glucagon-Like Peptide-1 Human ELISA (Multispecies specificity)

  • Regulatory status:RUO
  • Type:Competitive ELISA, Immobilized antibody
  • Other names:GLP-1
  • Species:Human, Mouse, Rat
Please select your region to see available products and prices.
Cat. No. Size Price


YK160 96 wells (1 kit)
PubMed Product Details
Technical Data

Cat # changed from RSCYK160R to YK160

Type

Competitive ELISA, Immobilized antibody

Applications

Plasma

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

0.206-50 ng/mL

Intra-assay (Within-Run)

Rat plasma - CV 5.36 - 6.60 Human plasma - CV 4.69 - 10.67

Inter-assay (Run-to-Run)

Rat plasma - CV 5.51 -18.87 Human plasma - CV 9.63 - 17.57

Spiking Recovery

Rat plasma - 102,6% Human plasma - 97,7%

Summary

Research topic

Diabetology - Other Relevant Products, Energy metabolism and body weight regulation, Animal studies

Summary

GLP-1 is a peptide hormone from the intestinal mucosa, which is produced from its precursor, proglucagon by post transnational processing. The mammalian proglucagon 1) is synthesized in the neuroendocrine L-cell of the intestine and the alpha-cells of the pancreas. It contains within its structure the sequences of glucagon and two glucagon-like peptides (GLP-1 and GLP-2) in tandem flanked at their amino and carboxyl termini by dibasic residues. GLP-1 is a 37 amino acids peptide and produced in the small intestine and in the pancreas in the human, in either C-terminal-amidated on glycine-extended form2) 3). GLP1 (7-36) amide and its receptor are present in several brain regions and may play a role in the physiological control of feeding4). Several reports have been presented as follows as to the biological activities of GLP-1. GLP-1 (7-37) and (7-36) amide is known as one of the most potent insulin secretagogues 5). GLP-1 (7-36) amide was supposed to improved glycemic control in patients with type 2 diabetes by increasing insulin secretion, by inhibiting glucagon secretion and by delaying gastric emptying rather than by altering extrapancreatic glucose metabolism6). Intravenous GLP-1 (7-37) and (7-36) amide could normalize fasting hyperglycaemia in type 2 diabetic patients7). Hyperglycaemia during parenteral nutrition could be controlled by exogenous GLP-1, whereas the chronic therapy of type 2 diabetes required GLP-1 derivatives with longer duration of action 8). Recombinant GLP-1 (7-36) amide was recently shown to cause significant weight loss in type 2 diabetics when administered for 6 weeks as a continuous subcutaneous infusion, 5-day treatment of hereby obese human subjects with GLP-1 at high doses by prandial subcutaneous infusion promptly slowed gastric emptying as a probable mechanism of action of increased satiety, decreased hunger and reduced food intake with an ensuing weight loss9). A G-protein-coupled receptor, GPR120, which is abundantly expressed in intestine, functions as a receptor for unsaturated long-chain FFAs (free fatty acids). The stimulation of GPR120 by FFAs promotes the secretion of GLP-1 in vitro (measured by YK160, Yanaihara Institute Inc) and in vivo, and increases circulation insulin, indicate that GPR120-mediated GLP-1 secretion induced by dietary FFAs is important in the treatment of diabetes10). All these approaches have shown remarkable efficacy in both experimental and clinical studies. The GLP-1-based therapy of type 2 diabetes, therefore, represents a new and attractive alternative11). Yanaihara Institute Inc. developed a quantitative EIA kit with high specificity and sensitivity (detection limit 0.206ng/mL) for rat/mouse/human GLP-1 (YK160) as a useful tool for these necessaries.

Product References (6)

References

  • Aronis KN, Chamberland JP, Mantzoros CS. GLP-1 promotes angiogenesis in human endothelial cells in a dose-dependent manner, through the Akt, Src and PKCpathways. Metabolism. 2013 Sep;62(9):1279-86. doi: 10.1016/j.metabol.2013.04.010.Epub 2013 May 14. PubMed PMID: 23684008; PubMed Central PMCID: PMC3755020. See more on PubMed
  • Choi SH, Leem J, Lee IK. Protective Effects of Gemigliptin, a DipeptidylPeptidase-4 Inhibitor, against Cisplatin-Induced Nephrotoxicity in Mice.Mediators Inflamm. 2017;2017:4139439. doi: 10.1155/2017/4139439. Epub 2017 Nov28. PubMed PMID: 29317794; PubMed Central PMCID: PMC5727799. See more on PubMed
  • Rauchenzauner M, Laimer M, Wiedmann M, Tschoner A, Salzmann K, Sturm W,Sandhofer A, Walser G, Luef G, Ebenbichler CF. The novel insulin resistanceparameters RBP4 and GLP-1 in patients treated with valproic acid: just asidestep? Epilepsy Res. 2013 May;104(3):285-8. doi:10.1016/j.eplepsyres.2012.10.004. Epub 2012 Nov 20. PubMed PMID: 23182413. See more on PubMed
  • Salis ER, Reith DM, Wheeler BJ, Broadbent RS, Medlicott NJ. Insulinresistance, glucagon-like peptide-1 and factors influencing glucose homeostasisin neonates. Arch Dis Child Fetal Neonatal Ed. 2017 Mar;102(2):F162-F166. doi:10.1136/archdischild-2015-309174. Epub 2016 Sep 2. PubMed PMID: 27589992. See more on PubMed
  • Vihonen H, Kuisma M, Salo A, Ångerman S, Pietiläinen K, Nurmi J. Mechanisms ofearly glucose regulation disturbance after out-of-hospital cardiopulmonaryresuscitation: An explorative prospective study. PLoS One. 2019 Mar25;14(3):e0214209. doi: 10.1371/journal.pone.0214209. eCollection 2019. PubMedPMID: 30908518; PubMed Central PMCID: PMC6433228. See more on PubMed
  • Zahradka P, Wright B, Weighell W, Blewett H, Baldwin A, O K, Guzman RP, TaylorCG. Daily non-soy legume consumption reverses vascular impairment due toperipheral artery disease. Atherosclerosis. 2013 Oct;230(2):310-4. doi:10.1016/j.atherosclerosis.2013.07.048. Epub 2013 Aug 6. PubMed PMID: 24075762. See more on PubMed
Summary References (11)

References to Glucagon-Like Peptide-1

  • Asarian L, Corp ES, Hrupka B, Geary N. Intracerebroventricular glucagon-like peptide-1 (7-36) amide inhibits sham feeding in rats without eliciting satiety. Physiol Behav. 1998 Jun 1;64 (3):367-72
  • Heinrich G, Gros P, Habener JF. Glucagon gene sequence. Four of six exons encode separate functional domains of rat pre-proglucagon. J Biol Chem. 1984 Nov 25;259 (22):14082-7
  • Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M, Sugimoto Y, Miyazaki S, Tsujimoto G. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med. 2005 Jan;11 (1):90-4
  • Holst JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev. 2002 Nov-Dec;18 (6):430-41
  • Mojsov S, Kopczynski MG, Habener JF. Both amidated and nonamidated forms of glucagon-like peptide I are synthesized in the rat intestine and the pancreas. J Biol Chem. 1990 May 15;265 (14):8001-8
  • Naslund E, King N, Mansten S, Adner N, Holst JJ, Gutniak M, Hellstrom PM. Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. Br J Nutr. 2004 Mar;91 (3):439-46
  • Nauck MA, Walberg J, Vethacke A, El-Ouaghlidi A, Senkal M, Holst JJ, Gallwitz B, Schmidt WE, Schmiegel W. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1. Regul Pept. 2004 Apr 15;118 (1-2):89-97
  • Nauck MA, Weber I, Bach I, Richter S, Orskov C, Holst JJ, Schmiegel W. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients. Diabet Med. 1998 Nov;15 (11):937-45
  • Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes. 1994 Apr;43 (4):535-9
  • Vella A, Shah P, Basu R, Basu A, Holst JJ, Rizza RA. Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. Diabetes. 2000 Apr;49 (4):611-7
  • Yanaihara N. [Recent advances in gastrointestinal hormones]. Hum Cell. 1990 Mar;3 (1):1-8
Related Products Docs